IL-37 Plays a Beneficial Role in Patients with Acute Coronary Syndrome

Background. Interleukin-37 (IL-37) acts as an inhibitor of innate and adaptive immunity. However, the exact role of IL-37 in the patients with acute coronary syndrome (ACS) remains to be elucidated. Methods. Patients were classified into 4 groups: normal coronary artery (NCA), stable angina (SA), un...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaobo Mao, Ruirui Zhu, Fangyuan Zhang, Yucheng Zhong, Kunwu Yu, Yuzhen Wei, Haitao Sun, Wenbin Xu, Quan Luo, Yue Wang, Yan Ding, Qiutang Zeng
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2019/9515346
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849467724379455488
author Xiaobo Mao
Ruirui Zhu
Fangyuan Zhang
Yucheng Zhong
Kunwu Yu
Yuzhen Wei
Haitao Sun
Wenbin Xu
Quan Luo
Yue Wang
Yan Ding
Qiutang Zeng
author_facet Xiaobo Mao
Ruirui Zhu
Fangyuan Zhang
Yucheng Zhong
Kunwu Yu
Yuzhen Wei
Haitao Sun
Wenbin Xu
Quan Luo
Yue Wang
Yan Ding
Qiutang Zeng
author_sort Xiaobo Mao
collection DOAJ
description Background. Interleukin-37 (IL-37) acts as an inhibitor of innate and adaptive immunity. However, the exact role of IL-37 in the patients with acute coronary syndrome (ACS) remains to be elucidated. Methods. Patients were classified into 4 groups: normal coronary artery (NCA), stable angina (SA), unstable angina (UA), and acute myocardial infarction (AMI). The circulating Treg, Th1, and Th17 frequencies were measured. The effect of IL-37 on stimulated peripheral blood mononuclear cells (PBMCs) and the influence of IL-37 on DCs were explored. In addition, the role of IL-37-treated tDCs on Treg cell expansion and the stability of these tDCs were also tested. Results. Our results showed that the circulating Treg frequencies were decreased, while Th1 and Th17 frequencies were increased in ACS patients, and that IL-37 expanded Tregs but suppressed Th1 and Th17 cells in activated PBMCs derived from ACS patients. Of note, IL-37-treated human DCs obtained a tolerogenic phenotype, and such tDCs promoted expansion of Tregs and decreased the Th1 and Th17 populations when cocultured with CD4+ T cells. Interestingly, IL-37-treated DCs from patients with ACS are phenotypically and functionally comparable to IL-37-treated DCs from NCA patients, and tolerogenic properties of IL-37-treated DCs were highly stable. Conclusion. In conclusion, our results reveal a beneficial role of IL-37 in the patients with ACS and suggest that autologous IL-37-treated tDCs may be a novel therapeutic strategy for the patients with ACS.
format Article
id doaj-art-e006372af59f4caab41af5669bcf7efe
institution Kabale University
issn 0962-9351
1466-1861
language English
publishDate 2019-01-01
publisher Wiley
record_format Article
series Mediators of Inflammation
spelling doaj-art-e006372af59f4caab41af5669bcf7efe2025-08-20T03:26:05ZengWileyMediators of Inflammation0962-93511466-18612019-01-01201910.1155/2019/95153469515346IL-37 Plays a Beneficial Role in Patients with Acute Coronary SyndromeXiaobo Mao0Ruirui Zhu1Fangyuan Zhang2Yucheng Zhong3Kunwu Yu4Yuzhen Wei5Haitao Sun6Wenbin Xu7Quan Luo8Yue Wang9Yan Ding10Qiutang Zeng11Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaDepartment of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaBackground. Interleukin-37 (IL-37) acts as an inhibitor of innate and adaptive immunity. However, the exact role of IL-37 in the patients with acute coronary syndrome (ACS) remains to be elucidated. Methods. Patients were classified into 4 groups: normal coronary artery (NCA), stable angina (SA), unstable angina (UA), and acute myocardial infarction (AMI). The circulating Treg, Th1, and Th17 frequencies were measured. The effect of IL-37 on stimulated peripheral blood mononuclear cells (PBMCs) and the influence of IL-37 on DCs were explored. In addition, the role of IL-37-treated tDCs on Treg cell expansion and the stability of these tDCs were also tested. Results. Our results showed that the circulating Treg frequencies were decreased, while Th1 and Th17 frequencies were increased in ACS patients, and that IL-37 expanded Tregs but suppressed Th1 and Th17 cells in activated PBMCs derived from ACS patients. Of note, IL-37-treated human DCs obtained a tolerogenic phenotype, and such tDCs promoted expansion of Tregs and decreased the Th1 and Th17 populations when cocultured with CD4+ T cells. Interestingly, IL-37-treated DCs from patients with ACS are phenotypically and functionally comparable to IL-37-treated DCs from NCA patients, and tolerogenic properties of IL-37-treated DCs were highly stable. Conclusion. In conclusion, our results reveal a beneficial role of IL-37 in the patients with ACS and suggest that autologous IL-37-treated tDCs may be a novel therapeutic strategy for the patients with ACS.http://dx.doi.org/10.1155/2019/9515346
spellingShingle Xiaobo Mao
Ruirui Zhu
Fangyuan Zhang
Yucheng Zhong
Kunwu Yu
Yuzhen Wei
Haitao Sun
Wenbin Xu
Quan Luo
Yue Wang
Yan Ding
Qiutang Zeng
IL-37 Plays a Beneficial Role in Patients with Acute Coronary Syndrome
Mediators of Inflammation
title IL-37 Plays a Beneficial Role in Patients with Acute Coronary Syndrome
title_full IL-37 Plays a Beneficial Role in Patients with Acute Coronary Syndrome
title_fullStr IL-37 Plays a Beneficial Role in Patients with Acute Coronary Syndrome
title_full_unstemmed IL-37 Plays a Beneficial Role in Patients with Acute Coronary Syndrome
title_short IL-37 Plays a Beneficial Role in Patients with Acute Coronary Syndrome
title_sort il 37 plays a beneficial role in patients with acute coronary syndrome
url http://dx.doi.org/10.1155/2019/9515346
work_keys_str_mv AT xiaobomao il37playsabeneficialroleinpatientswithacutecoronarysyndrome
AT ruiruizhu il37playsabeneficialroleinpatientswithacutecoronarysyndrome
AT fangyuanzhang il37playsabeneficialroleinpatientswithacutecoronarysyndrome
AT yuchengzhong il37playsabeneficialroleinpatientswithacutecoronarysyndrome
AT kunwuyu il37playsabeneficialroleinpatientswithacutecoronarysyndrome
AT yuzhenwei il37playsabeneficialroleinpatientswithacutecoronarysyndrome
AT haitaosun il37playsabeneficialroleinpatientswithacutecoronarysyndrome
AT wenbinxu il37playsabeneficialroleinpatientswithacutecoronarysyndrome
AT quanluo il37playsabeneficialroleinpatientswithacutecoronarysyndrome
AT yuewang il37playsabeneficialroleinpatientswithacutecoronarysyndrome
AT yanding il37playsabeneficialroleinpatientswithacutecoronarysyndrome
AT qiutangzeng il37playsabeneficialroleinpatientswithacutecoronarysyndrome